Barry J. Simon, M.D.
President & Chief Administrative Officer
Dr. Simon has served as the Company’s President & CEO from May 2007 through March 2015 and since then as its President & CAO. Dr. Simon previously held Vice President, senior level and advisory positions at F. Hoffmann-La Roche (VTX: ROG), Roche Labs, Connetics Corp. (NASDAQ: CNCT), Immunomedics (NASDAQ: IMMU), Immusol, NorthSound Capital, LLC, and HealthPro BioVentures. Dr. Simon has broad experience with product and portfolio divestitures and acquisitions, strategic licensing and joint ventures in addition to commercial product launches, IND & BLA regulatory filings, human-enabling programs, manufacturing, quality control and life cycle management. Dr. Simon worked across several therapeutic areas including oncology, virology, ophthalmology and dermatology on products and lauches including Xeloda®, Pegasys®, Fortovase®, Tamiflu®, Camptobell®, Boniva®, Cymeval®, ChelASE® and Accutane®. Dr. Simon attended corporate training programs by the London School of Business and the Amos Tuck School of Business at Dartmouth College. Dr. Simon trained clinically in Infectious Diseases, Anesthesiology and Internal Medicine and received his M.D. from the SUNY Downstate, Health Sciences Center in New York.